In this study, we provide evidence that KIFC2 may act as a potential oncogene to accelerate growth and confer resistance to ET and CDK4/6 inhibitors in HR+/HER2– BC (Figures 2 and 3 and Supplemental Figures 3 and 4). This evidence concerns the gene ERBB2 and breast cancer.